Active not recruitingNAINTERVENTIONAL

Investigating the Effectiveness of Vimida

This study is investigating a digital programme called 'Vimida' to help people who are still experiencing severe tiredness, known as fatigue, after having COVID-19. It involves 160 participants who will either use Vimida alongside their usual care or only receive their usual care. Researchers want to find out if Vimida can reduce fatigue symptoms over three and six months. To join, participants must be at least 18 years old, have been diagnosed with post-COVID-19 fatigue for at least three months, and have very noticeable fatigue. People are not eligible if their fatigue is due to another medical condition or if they are already in certain COVID-19 recovery programmes. The study hopes to offer new ways to help people struggling with long-term COVID-19 fatigue.

At a glance

Status

Active not recruiting

Phase

Sponsor

Gaia AG

Enrolment target

160

Start

13 Feb 2025

Estimated completion

01 Dec 2025

Long COVID Post COVID-19 Condition

What is this study about?

This study is looking into a digital programme called Vimida, which is designed to help people who are still suffering from severe tiredness, also known as fatigue, after they've had COVID-19. This ongoing tiredness is a common symptom of what's often called Long COVID or Post COVID-19 Condition.

The main aim is to see if using Vimida makes a real difference in reducing this fatigue compared to just receiving standard medical care. To do this, 160 people will take part. Half of them will use Vimida in addition to their usual care, and the other half will only receive their usual care. By comparing these two groups, the researchers hope to understand if Vimida is an effective tool.

Throughout the study, researchers will regularly check in with participants to measure their fatigue levels after three months and again after six months. They will also look at other important aspects of health, like mood, overall well-being, how well people can work or take part in social activities, and any other physical or anxious feelings. This detailed approach will help them understand the full impact of Vimida on people's lives.

Key takeaways

This study explores a digital tool called Vimida for post-COVID-19 fatigue.
It compares Vimida plus usual care against usual care alone.
Participation involves filling out questionnaires at 3 and 6 months.
The study aims to help people aged 18+ with long-term fatigue after COVID-19.
You need good German language skills to take part.

Who may be eligible?

To be part of this study, you need to be at least 18 years old, male, female, or non-binary. You must also have been diagnosed with ongoing tiredness (fatigue) after having COVID-19, and this fatigue should have lasted for at least three months since your COVID-19 infection.

Your fatigue levels also need to be quite noticeable when measured by a specific health questionnaire. You'll need to be willing to give your permission to take part and be able to understand German well enough, as the program and study information will be in German.

You won't be able to join if your fatigue can be explained by another known health condition, such as certain serious illnesses or depression. Also, if you're currently in another major recovery programme designed to help with the effects of COVID-19, you won't be able to take part in this study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been experiencing significant tiredness (fatigue) for at least three months following COVID-19?
Is your fatigue *not* explained by another medical condition?
Are you able to speak and understand German well?
Are you currently *not* in another major COVID-19 recovery program?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you'll be randomly put into one of two groups. One group will get access to the Vimida digital program along with their usual medical care. The other group will only receive their usual medical care.

There are no in-person visits to a clinic. Your eligibility will be confirmed through a phone or video call. You'll be asked to complete questionnaires to measure your fatigue and other symptoms after three months. There will be another follow-up assessment with questionnaires after six months. The total duration of your active participation, including assessments, will be six months.

Potential risks and benefits

Participating in this study might offer you the benefit of trying a new digital program designed to help with post-COVID-19 fatigue. It could potentially improve your energy levels and overall well-being. However, there's also a chance that Vimida might not work for everyone, or you might be in the group that only receives usual care. The main risk is the time commitment for filling out questionnaires. You are free to withdraw from the study at any time without giving a reason, and this will not affect your usual medical care.

Locations (1)

GAIA
Verified postcode
Hamburg, Germany

Common questions

What is Vimida?

Vimida is a digital program that the study is investigating to see if it can help people with ongoing tiredness after COVID-19.

What is 'usual care'?

Usual care refers to the standard medical treatments or advice you would normally receive from your doctor or healthcare provider for your condition.

How long will the study last for me?

If you take part, your involvement will last for six months, involving assessments at three and six months.

Do I need to speak German?

Yes, you need to have sufficient German language skills to participate as the program and study materials are in German.

What if my fatigue is caused by something else?

You won't be able to join the study if your fatigue is known to be caused by another medical or mental health condition.